he gene therapy approvals keep on coming with BioMarin’s Roctavian receiving approval today. The therapy could reduce or free hemophilia A patients from "bleeds" for years.
https://t.co/UFDJrVGNJK
#genetherapy#fda#roctavian#bcsrisknavigator
After delays, Sarepta Therapeutics Elevidys, the First Gene Therapy to Treat Duchenne Muscular Dystrophy, finally crosses FDA finish line at $3.2M!
https://t.co/NplJxPJAI6
#genetherapy
MRM is back on the road - this time to Nashville! We are looking forward to seeing everyone at the 2023 @MeritainHealth Local Market Development Conference.
Lots of learning and fun so far at Benefit Advisors Network Winter Conference! Looking forward to another great day of discussions, especially around our special incentive for BAN Agencies. #BANFL2023
MRM is looking forward to seeing everyone at the upcoming 2023 Benefit Advisors Network (BAN) Winter Conference! Be sure to find us to hear more about special incentives that may be available. #BANFL2023
🔟 days until #BANFL2023! Looking forward to connecting with our Benefit Advisors Network (BAN) colleagues at the upcoming winter conference in Orlando. Comment below if we will see you there!
Today marks the beginning of National Hispanic Heritage Month. From September 15 to October 15, we celebrate and recognize the contributions of the Hispanic community.
#TeamMRM had a great time with @HealthPlansInc at the Daniel White Memorial Charity Golf Tournament this week. Great golf, and great group of #stoploss professionals!